About Very High Triglycerides
Hypertriglyceridemia, a disease where patients have high blood levels of triglycerides, is associated with increased risk of coronary heart disease even after LDL-cholesterol targets have been achieved. Very high triglycerides are associated with an increased risk of developing pancreatitis. There are approximately 5 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides, fenofibrate and omega-3 fatty acids, while effective, also cause significant elevations in LDL-cholesterol.
About Mixed Dyslipidemia
The prevalence of mixed dyslipidemia (characterized by elevated triglycerides and low HDL-cholesterol), is currently more than 16 million patients in the US and is rising in tandem with the ongoing obesity epidemic. Treatment options are limited and the leading products are associated with tolerability issues including flushing, elevated liver enzymes and increased risk of rhabdomyolysis when used in combination with statin drugs.
Essentialis is a pharmaceutical company based in Carlsbad, CA focused on
the development of breakthrough medicines for the treatment of cardiovascular
and metabolic diseases. The company's portfolio of products is targeted at the
ATP-sensitive potassium channel, a metabolically-regulated membrane protein
whose modulation has the potential to impact a wide range of cardiovascular
and metabolic diseases. The company's lead product is in Phase 2 studies in
dyslipidemic subjects and is entering a Phase 1 study in type I diabet
|SOURCE Essentialis Inc|
Copyright©2008 PR Newswire.
All rights reserved